Zymeworks Inc. announced in connection with the Restructuring, effective January 19, 2022, the Company terminated the employment of Dr. Anthony Polverino, Executive Vice President, Early Development & Chief Scientific Officer and in connection with the Restructuring, effective January 19, 2022, the Company terminated the employment of Ms. Kathryn O'Driscoll, Chief People Officer.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.175 USD | +0.60% | +2.85% | -13.28% |
02/05 | Transcript : Zymeworks Inc., Q1 2024 Earnings Call, May 02, 2024 | |
02/05 | Zymeworks Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.28% | 650M | |
+3.77% | 106B | |
+7.54% | 23.47B | |
-13.99% | 21.9B | |
-6.59% | 18.77B | |
-37.26% | 17.85B | |
-7.69% | 16.78B | |
+7.50% | 14.41B | |
+39.78% | 12.86B | |
+320.98% | 8.78B |
- Stock Market
- Equities
- ZYME Stock
- News Zymeworks Inc.
- Zymeworks Inc. Announces Management Changes